Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-500,000
Closed -$12.4M 1771
2025
Q4
$12.4M Hold
500,000
0.02% 305
2025
Q3
$12.7M Hold
500,000
0.06% 259
2025
Q2
$12.1M Hold
500,000
0.09% 238
2025
Q1
$12.7M Hold
500,000
0.12% 195
2024
Q4
$13.3M Buy
500,000
+375,000
+300% +$10.2M 0.11% 182
2024
Q3
$3.62M Buy
+125,000
New +$3.65M 0.03% 442
2023
Q4
Sell
-498,300
Closed -$16.5M 1097
2023
Q3
$16.5M Sell
498,300
-50,000
-9% -$1.77M 0.19% 125
2023
Q2
$20.1M Buy
+548,300
New +$21.3M 0.22% 102
2022
Q2
Sell
-1,227,100
Closed -$63.5M 1418
2022
Q1
$63.5M Buy
+1,227,100
New +$63.7M 0.74% 16

Other funds holding PFE

LMR Partners's PFE Position: Q1 2026 in Review

LMR Partners reduced its Pfizer (PFE) stake by 92% in Q1 2026, selling an estimated $12.4M and leaving 39,989 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #960.

LMR Partners first reported a position in PFE in Q4 2015 and has held it in 17 quarters since. The position peaked at $16.9M in Q4 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • LMR Partners held 39,989 shares of Pfizer worth $1.12M as of Q1 2026.
  • LMR Partners sold 466,562 Pfizer shares in Q1 2026, an estimated $12.4M.
  • Pfizer made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #960 holding.
  • LMR Partners first reported a position in Pfizer in Q4 2015 and has held it in 17 quarters since.
  • LMR Partners's Pfizer position peaked at $16.9M in Q4 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.